Cargando…
P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621484/ http://dx.doi.org/10.1097/01.HS9.0000890992.42939.53 |
| _version_ | 1784821566084743168 |
|---|---|
| author | Erenmalm, Axel Linderoth, Johan |
| author_facet | Erenmalm, Axel Linderoth, Johan |
| author_sort | Erenmalm, Axel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621484 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96214842022-11-01 P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience Erenmalm, Axel Linderoth, Johan Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621484/ http://dx.doi.org/10.1097/01.HS9.0000890992.42939.53 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Erenmalm, Axel Linderoth, Johan P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience |
| title | P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience |
| title_full | P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience |
| title_fullStr | P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience |
| title_full_unstemmed | P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience |
| title_short | P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience |
| title_sort | p106: dose intensive brentuximab vedotin for platinum resistant recurrent hodgkin lymphoma is a feasible treatment option - a single center experience |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621484/ http://dx.doi.org/10.1097/01.HS9.0000890992.42939.53 |
| work_keys_str_mv | AT erenmalmaxel p106doseintensivebrentuximabvedotinforplatinumresistantrecurrenthodgkinlymphomaisafeasibletreatmentoptionasinglecenterexperience AT linderothjohan p106doseintensivebrentuximabvedotinforplatinumresistantrecurrenthodgkinlymphomaisafeasibletreatmentoptionasinglecenterexperience |